Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318497 · ClinicalTrials.gov registry record · Phase 2
Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03318497 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT03318497, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict overall survival at 1 and 2 years and progression free survival at 6 months and 1 year in patients with borderline resectable or locally advanced, pancreatic adenocarcinoma.
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- DRUG 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03318497
The ClinicalTrials.gov registry entry for NCT03318497 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography is the first listed.
NCT03318497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03318497 about?
NCT03318497 is a clinical study titled "Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma". To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict overall survival at 1 and 2 years and progression free survival at 6 months and 1 year in patients with borderline rese...
What is the current status of trial NCT03318497?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-12-11. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT03318497?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT (DRUG).
Who is sponsoring clinical trial NCT03318497?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.